The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis.

Suppr

超能文献

作者信息

Ellard G A

出版信息

Tubercle. 1984 Sep;65(3):211-27. doi: 10.1016/0041-3879(84)90079-5.

DOI:10.1016/0041-3879(84)90079-5

PMID:6385429

Abstract

摘要

相似文献

The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis.

Tubercle. 1984 Sep;65(3):211-27. doi: 10.1016/0041-3879(84)90079-5.

Lack of relationship between hepatic toxicity and acetylator phenotype in three thousand South Indian patients during treatment with isoniazid for tuberculosis.

Am Rev Respir Dis. 1984 Jan;129(1):58-61. doi: 10.1164/arrd.1984.129.1.58.

[The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis].

Rev Mal Respir. 1984;1(4):207-19.

[The potential clinical significance of the isoniazid acetylator phenotype in the treatment of pulmonary tuberculosis].

Cas Lek Cesk. 1984 Feb 10;123(6):158-64.

The incidence of the acetylator phenotype of isoniazid in healthy and in pulmonary tuberculosis subjects in Bihar.

J Assoc Physicians India. 1978 May;26(5):353-60.

The hepatotoxicity of isoniazid among the three acetylator phenotypes.

Am Rev Respir Dis. 1981 May;123(5):568-70. doi: 10.1164/arrd.1981.123.5.568a.

Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis.

Clin Pharmacol Ther. 1976 May;19(5 Pt 2):610-25. doi: 10.1002/cpt1976195part2610.

Acetylation phenotype and hepatotoxicity in the treatment of tuberculosis in children.

Pediatrics. 1986 Jun;77(6):912-5.

[Incidence of hepatic changes in relation to the isoniazid acetylator phenotype].

Medicina (B Aires). 1980 Jul-Aug;40(4):382-6.

[Clinical pharmacology of isoniazid (a review of the literature)].

Probl Tuberk. 1979 Jan(1):18-26.

引用本文的文献

Effect of Multicomponent Exercise Program on Pain and Functional Mobility in Antitubercular Drug Therapy-Induced Peripheral Neuropathy in Pulmonary Tuberculosis Survivors.

Cureus. 2024 Jul 26;16(7):e65431. doi: 10.7759/cureus.65431. eCollection 2024 Jul.

Isoniazid acetylation phenotypes in the Sudanese population; findings and implications.

J Clin Tuberc Other Mycobact Dis. 2019 Sep 6;17:100120. doi: 10.1016/j.jctube.2019.100120. eCollection 2019 Dec.

Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid.

J Antimicrob Chemother. 2019 Jan 1;74(1):139-148. doi: 10.1093/jac/dky378.

Prevention of isoniazid toxicity by NAT2 genotyping in Senegalese tuberculosis patients.

Toxicol Rep. 2016 Oct 17;3:826-831. doi: 10.1016/j.toxrep.2016.10.004. eCollection 2016.

Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.

Antimicrob Agents Chemother. 2015 Oct 12;60(1):92-8. doi: 10.1128/AAC.00693-15. Print 2016 Jan.

Alcoholic liver disease: a synopsis of the Charles Lieber's Memorial Symposia 2009-2012.

Alcohol Alcohol. 2014 Jul-Aug;49(4):373-80. doi: 10.1093/alcalc/agu021. Epub 2014 May 9.

Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients.

Antimicrob Agents Chemother. 2013 Jul;57(7):3208-13. doi: 10.1128/AAC.02599-12. Epub 2013 Apr 29.

Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy.

Clin Infect Dis. 2012 Jul;55(2):169-77. doi: 10.1093/cid/cis353. Epub 2012 Mar 30.

Nervous system effects of antituberculosis therapy.

CNS Drugs. 2010 Aug;24(8):655-67. doi: 10.2165/11534340-000000000-00000.

The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid.

Eur J Clin Pharmacol. 2007 Jul;63(7):633-9. doi: 10.1007/s00228-007-0305-5. Epub 2007 May 16.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验